In Segment A, individuals will get different doses and schedules of oral ABBV-744 tablet to recognize Harmless dosing regimen. Added contributors will probably be enrolled for the discovered monotherapy dosign regimen. In Segment B, individuals will obtain oral ruxolitinib and ABBV-744 might be given as "incorporate-on" therapy. In Section C, https://abbv-744brd4inhibitorcanc24680.newbigblog.com/38192661/abbv-744-in-clinical-trials-for-non-small-cell-lung-cancer-nsclc-options